Skip to main content

Synalar

Generic: fluocinolone acetonide

Verified·Apr 23, 2026
Manufacturer
Medimetriks
NDC
43538-900
RxCUI
1191315
Route
TOPICAL
ICD-10 indication
L30.9

Affordability Check

How much will you actually pay for Synalar?

In 30 seconds, see every legitimate way to afford Synalar — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Synalar

What is this medication?

Synalar is a prescription topical corticosteroid that contains the active ingredient fluocinolone acetonide. It is primarily used to treat a wide variety of skin conditions characterized by inflammation, redness, and persistent itching. The medication works by suppressing the immune response in the local area where it is applied, which helps to reduce the swelling and discomfort associated with irritated skin. It is manufactured in different forms, including creams, ointments, and topical solutions, to ensure it can be applied effectively to different parts of the body and various types of skin lesions.

Doctors typically prescribe Synalar for the management of conditions such as eczema, psoriasis, seborrheic dermatitis, and allergic contact dermatitis. Because it is classified as a medium-potency steroid, it is effective for moderate symptoms but must be used strictly according to a healthcare provider's instructions. Patients are generally advised to apply a thin film to the affected area and avoid using occlusive dressings, like bandages or plastic wrap, unless specifically told to do so. To minimize the risk of side effects such as skin thinning or systemic absorption, the medication is usually intended for short-term use rather than long-term daily application.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Synalar. Official source: DailyMed (NLM) · Label effective Jul 18, 2024

Indications and usage
INDICATIONS AND USAGE SYNALAR ® Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.
Dosage and administration
DOSAGE AND ADMINISTRATION SYNALAR ® Cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse reactions
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria
Use in pregnancy
Pregnancy Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Synalar appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

1%

41 of 5,509 plans

Most common tier

Tier 4

On 100% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 4 (non-preferred brand)5
100%

Step therapy: 0% of formularies

Quantity limits: 0% of formularies

Coverage breadth: 5 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.